中危急性肺栓塞患者的氧疗:一项随机试验
本试点试验将无低氧血症的中危肺栓塞伴右心室扩大患者随机分配至抗凝联合48小时补氧组或单纯抗凝组。48小时后右心室大小正常化比例在氧疗组为42.4%、环境空气组为21.6%(P=.08),差异无统计学意义。试验因COVID-19疫情提前终止,样本量有限。
要点
- 无低氧血症中危肺栓塞患者补氧48小时未显著提高右心室大小正常化比例(42.4% vs 21.6%,P=.08)。
- 氧疗组右心室/左心室比值从基线1.28±0.28降至48小时1.01±0.16(P<.001)。
- 试验因疫情提前终止,仅70例有主要结局数据,结论受限。
核心结论
- 在样本量有限的条件下,与仅抗凝相比,补氧未显著增加无低氧血症中危肺栓塞患者48小时后右心室/左心室比值正常化的比例。
- 该试点试验显示部分次要疗效结局有改善,为开展确定性临床结局试验提供了支持。
研究设计与样本
- 试点随机对照试验,纳入无低氧血症的稳定肺栓塞伴超声心动图右心室扩大患者。
- 随机分配至抗凝联合前48小时补氧组或单纯抗凝组,共70例有主要结局数据(平均年龄67.3±16.1岁,女性36例[51.4%])。
- 主要结局为随机化48小时后超声心动图右心室大小正常。
- 次要疗效结局为随机化48小时和7天时右心室/左心室直径比值相对于基线比值的变化。
- 试验注册号:ClinicalTrials.gov NCT04003116。
主要发现
- 随机化48小时后,氧疗组33例中14例(42.4%)右心室大小正常化,环境空气组37例中8例(21.6%)正常化(P=.08)。
- 氧疗组平均右心室/左心室比值从基线1.28±0.28降至48小时1.01±0.16(P<.001)。
- 环境空气组平均右心室/左心室比值从基线1.21±0.18降至48小时1.08±0.19(P<.01)。
- 90天时发生1例大出血和1例死亡,均位于环境空气组。
临床怎么用
- 对于无低氧血症的中危肺栓塞伴右心室扩大患者,补氧48小时未显著改善主要超声心动图结局,不应常规以改善右心室大小为目的进行补氧。
局限性
- 研究因COVID-19疫情提前终止,入组患者数量少,统计效能有限。
- 主要结局差异无统计学意义,需更大规模确定性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of supplemental oxygen therapy in patients with intermediate-risk pulmonary embolism (PE) who do not have hypoxemia at baseline is uncertain. RESEARCH QUESTION: Does supplemental oxygen improve echocardiographic parameters in nonhypoxemic patients with intermediate-risk PE? STUDY DESIGN AND METHODS: This pilot trial randomly assigned nonhypoxemic patients with stable PE and echocardiographic right ventricle (RV) enlargement to receive anticoagulation plus supplemental oxygen for the first 48 h vs anticoagulation alone. The primary outcome was normal echocardiographic RV size 48 h after randomization. Secondary efficacy outcomes were the numerical change in the RV to left ventricle (LV) diameter ratio measured 48 h and 7 days after randomization with respect to the baseline ratio measured at inclusion. RESULTS: The study was stopped prematurely because of the COVID-19 pandemic after recruiting 70 patients (mean ± SD age, 67.3 ± 16.1 years; 36 female [51.4%]) with primary outcome data. Forty-eight h after randomization, normalization of the RV size occurred in 14 of the 33 patients (42.4%) assigned to oxygen and in eight of the 37 patients (21.6%) assigned to ambient air (P = .08). In the oxygen group, the mean RV to LV ratio was reduced from 1.28 ± 0.28 at baseline to 1.01 ± 0.16 at 48 h (P < .001); in the ambient air group, mean RV to LV ratios were 1.21 ± 0.18 at baseline and 1.08 ± 0.19 at 48 h (P < .01). At 90 days, one major bleeding event and one death (both in the ambient air group) had occurred. INTERPRETATION: In analyses limited by a small number of enrollees, compared with ambient air, supplemental oxygen did not significantly increase the proportion of patients with nonhypoxemic intermediate-risk PE whose RV to LV ratio normalized after 48 h of treatment. This pilot trial showed improvement in some ancillary efficacy outcomes and provides support for a definitive clinical outcomes trial. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04003116; URL: www. CLINICALTRIALS: gov.
引用
- Barrios, Durán, Rodríguez, et al. Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism: A Randomized Trial. Chest. 2023. PMID: 37717936. doi:10.1016/j.chest.2023.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。